Search results for: rituximab

Range of Insurance Issues Challenge Rheumatology

Thomas R. Collins | February 12, 2020

ACR representatives updated members on recent insurance issues…

FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns

Susan Bernstein | February 12, 2020

Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…

Coverage & Reimbursement Challenges: Updates from the ACR Insurance Subcommittee Chair

Chris Phillips, MD | February 7, 2020

The ACR Insurance Subcommittee is working to address specialty pharmacy requirements for in-office treatments, elimination of consultation codes and other coverage and reimbursement challenges.

The Care & Treatment of Myositis: Creatinine Kinase Level Isn’t Gospel & Other Recommendations

Thomas R. Collins | January 28, 2020

During a session at the 2019 ACR/ARP Annual Meeting, Lisa Christopher-Stine, MD, MPH, provided valuable recommendations and practical insights into the care and treatment of myositis patients…

Sjögren’s Syndrome in Kids: Diagnostic Challenges & Treatment Options

Sara M. Stern, MD, Matthew L. Basiaga, DO, MSCE, & Scott M. Lieberman, MD, PhD | January 17, 2020

A 14-year-old girl is referred to your office for fatigue and arthralgias. While you’re obtaining her past medical history, she divulges that she has had four episodes of bilateral parotitis, each lasting two weeks. An otolaryngologist evaluated her. She lacked sicca symptoms, had a normal complete blood count (CBC), normal inflammatory markers and a negative…

Seq & Ye Shall Find

Philip Seo, MD, MHS | January 16, 2020

I nodded, gravely. I was recently privileged to attend a symposium on eosinophils. I realize that this sounds odd. And it was odd, mainly because I’m not an eosinophil expert. Still, they were in need of someone who knew something about eosinophilic granulomatosis with polyangiitis, so I managed to sneak in through the back door….

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Jason Liebowitz, MD, FACR | December 18, 2019

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondyloarthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

Case Report: Rheumatoid Arthritis-Associated Restrictive Pericarditis

Scott Rodriguez, MD, Kenton Powell, MD, & Daniel Albert, MD | November 17, 2019

Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects approximately 1% of the adult population, and involvement of extra-articular tissue occurs in approximately 40% of patients over their lifetimes.1 RA-associated pericardial disease is an uncommon complication, and surgery is the only definitive therapy—according to current literature. In this report, we present the case of…

Researchers Seek the Best Methods to Maintain Remission in Vasculitis

Jason Liebowitz, MD, FACR | October 18, 2019

MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…

Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases

Caroline Humer | October 9, 2019

NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…